Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy

Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy
复制标题

中国 B 细胞急性淋巴细胞白血病患者 CAR-T 治疗后 T 细胞库改变的定量特征

DOI:
10.1038/s41409-019-0625-y
复制
发表时间:
2019-12-01
影响因子:
4.8
通讯作者:
Huang, He
Huang, He
中科院分区:
医学3区
文献类型:
--
作者:
Wang, Xiujian;Hu, Yongxian;Huang, He

文献摘要

被引文献

相似文献

嵌合抗原受体(CAR)T细胞疗法在急性淋巴细胞白血病(ALL)中显示出有效的抗白血病活性,为难治性/复发性患者带来了新的希望。然而,CAR-T疗法对宿主免疫系统的影响尚未得到很好的阐明。因此,我们应用高通量T细胞受体β链测序来追踪B细胞ALL患者中CAR-T疗法诱导的T细胞库的动态变化。正在观察 6 名完全缓解的中国患者,在 CAR-T 治疗前后的连续时间点采集其血液样本、骨髓样本和输注 CAR-T 样本。我们观察到 CAR-T 给药后,外周血和骨髓中 T 细胞库的 TCR 多样性降低,克隆性增加。血液和骨髓中的持久性 T 细胞克隆在白血病细胞破坏后扩增,但在 CAR T 细胞池中几乎检测不到。我们的结果首次证明 CAR-T 疗法可以刺激患者体内 CAR 阴性 T 细胞的克隆增殖。考虑到其他研究组的动物实验结果表明,CAR-T疗法可以促进肿瘤抗原特异性T细胞的增殖,并且这些T细胞克隆是在白血病细胞被破坏后出现的,因此它们很可能是肿瘤抗原特异性的。
Chimeric antigen receptor (CAR) T-cell therapy has displayed potent anti-leukemia activity in acute lymphocytic leukemia (ALL), acting as a new ray of hope to refractory/relapsed patients. However, the influence of CAR-T therapy on host immune system has not been well elucidated. Thus, We applied high-throughput T cell receptor beta chain sequencing to track the dynamic change of T-cell repertoire induced by CAR-T therapy in B-cell ALL patients. Six Chinese patients achieving complete remission were under observation, whose blood samples, bone marrow samples and infused CAR-T samples were collected at serial time points before and after CAR-T therapy. We observed decreased TCR diversity and increased clonality of T-cell repertoire in both peripheral blood and bone marrow after CAR-T administration. The persistent T cell clones in blood and bone marrow expanded following leukemic cell destruction and were barely detected in CAR T-cell pool. For the first time, our results demonstrated CAR-T therapy could stimulate the clonal proliferation of CAR-negative T cells in patients. Considering other groups' animal results indicating that CAR-T therapy could facilitate the proliferation of tumor antigen-specific T cells and that the emergence of these T cell clones followed the destruction of leukemic cells, they are most likely tumor antigen-specific.